查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999359

肝癌診斷市場：2026年至2032年全球市場預測，依分期、檢測類型、技術及最終用戶分類

Liver Cancer Diagnostics Market by Disease Stage, Test Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肝癌診斷市場價值將達到 107 億美元，到 2026 年將成長至 113.8 億美元，到 2032 年將達到 169.7 億美元，複合年成長率為 6.81%。

主要市場統計數據
基準年 2025 107億美元
預計年份：2026年 113.8億美元
預測年份 2032 169.7億美元
複合年成長率 (%) 6.81%

簡要概述正在重新定義肝癌治療診斷路徑和相關人員優先事項的臨床、技術和政策促進因素的演變。

肝癌診斷領域正經歷快速發展，其驅動力包括技術創新、臨床實踐的變革以及政策趨勢的轉變。本執行摘要概述了影響診斷路徑、診斷方法應用以及相關人員決策的最重要趨勢。接下來的章節將對臨床趨勢、監管影響、技術成熟度和營運限制進行綜合分析，揭示這些因素如何塑造診斷領域相關人員所處的競爭格局和臨床環境。

分子診斷、影像解析度和保險公司可接受的證據創建方面的創新融合如何改變肝癌診斷途徑。

一系列變革正在重塑我們對肝癌的檢測、表徵和治療方式。分子診斷和高靈敏度成像技術的進步使臨床醫生能夠在疾病早期進行干預，提高腫瘤表徵的準確性，同時減少對高侵入性操作的依賴。同時，循環腫瘤DNA (ctDNA) 和微型RNA(miRNA) 檢測與已建立的蛋白質標記的整合，正在促進混合診斷策略的發展，從而在不同的臨床環境中平衡靈敏度和操作可行性。

我們將評估近期關稅調整對診斷服務和技術整體的籌資策略、供應商選擇和資本分配決策的影響。

2025年關稅的實施和貿易政策的調整，為診斷耗材、影像設備和分子檢測平台的籌資策略增添了新的變數。供應鏈經理和採購人員正在透過重新評估採購區域、協商長期供應商合約以及考慮本地組裝和檢驗的二級供應商等方式來應對這些變化，以降低進口關稅及其導致的成本波動帶來的風險。

詳細的細分分析揭示了疾病進展、醫療保健環境、實驗室架構和成像方式如何共同決定診斷技術的採用模式和投資重點。

基於細分的洞察揭示了疾病進展各階段、終端用戶畫像、檢測類型和技術模式的清晰需求和運作模式。就疾病進展而言，晚期流程優先考慮確診性檢測和分子譜分析，以指南標靶治療；而早期流程則優先考慮高靈敏度篩檢技術和微創診斷，以支持根治性介入。這種二分法導致了侵入性和非侵入性檢測方式的採用曲線存在差異。

對比區域趨勢，可以發現醫療保健基礎設施、報銷途徑和資本投資如何影響全球主要市場診斷技術的採用。

區域趨勢呈現出顯著的異質性，這源自於醫療基礎設施、法規結構、報銷機制和臨床實踐模式的差異。在美洲，診斷生態系統強調在連網醫療系統和學術機構內快速採用創新技術，推動了三級醫療和門診診斷網路對整合分子和影像解決方案的需求。該地區通常在將臨床試驗證據轉化為臨床實踐方面發揮主導作用，對先進的分子譜分析以支持精準腫瘤學研究表現出強烈的需求。

競爭和合作趨勢表明，一體化的產品組合、強大的實證策略和供應鏈韌性將決定診斷市場的長期定位。

肝癌診斷領域的競爭格局由成熟的診斷試劑製造商、專業的分子診斷公司、影像設備供應商和臨床實驗室網路組成。市場領導憑藉其廣泛的產品組合保持差異化優勢，這些產品組合涵蓋影像硬體、檢測試劑盒以及用於數據解讀和工作流程整合的整合軟體解決方案。中型企業和創新Start-Ups則透過開發針對特定領域的檢測方法、次世代定序(NGS) 應用以及微創生物標記組合，為滿足早期檢測和分子分型方面尚未滿足的需求做出貢獻。

為產品、臨床和銷售團隊制定可操作的策略重點，以加速產品推廣、降低供應風險並展現永續的臨床價值。

產業領導者應優先考慮制定一致的策略，協調產品開發、臨床證據產生和上市時間模式，以最大限度地提高臨床應用率和商業性吸引力。投資進行前瞻性研究，以證明其在早期檢測和治療分層方面的臨床效用，預計將對指南採納和支付方支持產生重大影響。同時，應為門診診所、診斷中心、醫院和實驗室制定客製化的實施藍圖，以確保解決方案能夠根據各機構的實際情況進行最佳化。

採用混合方法研究途徑，結合專家訪談、臨床文獻整合和技術評估，以檢驗操作和臨床見解。

本分析採用混合方法，兼顧定量檢驗和定性情境化，整合一手和二手資訊。一級資訊來源包括對臨床專業人員、實驗室經理、採購經理和產業高管的訪談，以了解實際營運和策略意圖。這些觀點經過系統編碼，以識別診斷技術應用、工作流程整合和支付方參與的共同主題。

結論強調了在證據生成、工作流程整合和供應彈性方面的合作投資將如何塑造診斷領域的領導地位。

總之，肝癌的診斷格局正朝著整合式、多模態方法轉變，力求在所有醫療機構中平衡敏感性、特異性和操作可行性。基因組檢測和影像技術的進步不斷拓展診斷工具，實現更早期的檢測和更精準的分期，進而輔助治療決策。政策和採購趨勢，包括關稅相關影響，正推動更具策略性的採購和資本規劃，以確保醫療服務的持續可近性和營運的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 肝癌診斷市場（依疾病分期分類）

  • 晚期
  • 早期的

第9章 肝癌診斷市場：檢測類型

  • 生物標記
    • 遺傳標記
      • ctDNA檢測
      • 微型RNA檢測
    • 蛋白質標記物
      • AFP偵測
      • DCP 測試
  • 切片檢查
    • 核心針穿刺切片
    • 細針穿刺切片檢查
  • 基因檢測
    • 次世代定序
    • PCR分析

第10章 肝癌診斷市場：依技術分類

  • 電腦斷層掃描
  • MRI
  • PET
  • 超音波檢查

第11章 肝癌診斷市場：依最終用戶分類

  • 門診治療
  • 診斷中心
  • 醫院
  • 研究所

第12章 肝癌診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肝癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肝癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國肝癌診斷市場

第16章：中國肝癌診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amgen inc
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Boston Scientific Corporation
  • Danaher Corporation
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-3A2E844FE71E

The Liver Cancer Diagnostics Market was valued at USD 10.70 billion in 2025 and is projected to grow to USD 11.38 billion in 2026, with a CAGR of 6.81%, reaching USD 16.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.70 billion
Estimated Year [2026] USD 11.38 billion
Forecast Year [2032] USD 16.97 billion
CAGR (%) 6.81%

A concise overview of the shifting clinical, technological, and policy drivers that are redefining diagnostic pathways and stakeholder priorities in liver cancer care

The landscape of liver cancer diagnostics is undergoing rapid evolution driven by technological innovation, clinical practice changes, and shifting policy dynamics. This executive summary distills the most consequential developments shaping diagnosis pathways, diagnostic modality adoption, and stakeholder decision-making. The following pages synthesize clinical trends, regulatory influences, technology maturation, and operational constraints that together define the competitive and clinical milieu for diagnostic stakeholders.

The intent of this analysis is to provide an actionable synthesis that supports strategic planning across product development, commercial operations, and health system adoption. Emphasis is placed on how multi-modal diagnostic approaches are being integrated into care pathways, where evidence generation is accelerating uptake, and how payer considerations are influencing provider implementation. This section establishes the foundation for deeper insights, highlighting the interplay between diagnostic sensitivity and specificity requirements, the need for minimally invasive testing, and the push for earlier detection to enable curative-intent interventions.

Throughout the report, we prioritize clarity and relevance for leaders responsible for clinical strategy, regulatory affairs, reimbursement planning, and commercial deployment. Transitional commentary connects trends in biomarker science and imaging technology with pragmatic considerations in laboratory operations and ambulatory diagnostics, setting the stage for the more detailed thematic and regional analyses that follow.

How converging innovations in molecular diagnostics, imaging resolution, and payer-friendly evidence generation are transforming liver cancer diagnostic pathways

A confluence of transformative shifts is reshaping how liver cancer is detected, characterized, and managed. Advancements in molecular diagnostics and high-sensitivity imaging are enabling clinicians to move earlier in the disease course, improving the granularity of tumor characterization while reducing reliance on highly invasive procedures. Concurrently, the integration of circulating tumor DNA and microRNA assays with established protein markers is fostering hybrid diagnostic strategies that balance sensitivity with operational feasibility in diverse care settings.

Regulatory and reimbursement frameworks are adapting to evidence generated by real-world data and prospective validation studies, which in turn accelerates adoption when clinical utility is demonstrated. Healthcare providers are increasingly adopting multi-disciplinary diagnostic algorithms that leverage imaging modalities in parallel with targeted biomarker panels to support treatment stratification. This shift is complemented by laboratory workflow innovations and decentralized testing models that expand access in ambulatory care and diagnostic center environments.

Finally, technological convergence-where next-generation sequencing platforms, advanced bioinformatics, and higher-resolution imaging intersect-creates pathways for precision diagnostics that inform individualized therapeutic choices. These shifts collectively reduce diagnostic uncertainty, shorten time to definitive diagnosis, and generate more actionable data for oncologists, interventional radiologists, and multidisciplinary tumor boards.

Assessing how recent tariff adjustments are reshaping procurement strategies, supplier selection, and capital allocation decisions across diagnostic services and technologies

The introduction of tariffs and trade policy adjustments in 2025 has introduced new variables into procurement strategies for diagnostic consumables, imaging equipment, and molecular testing platforms. Supply chain managers and procurement leads are responding by reassessing sourcing geographies, negotiating longer-term supplier agreements, and exploring local assembly or validated secondary suppliers to mitigate exposure to import duties and associated cost volatility.

Clinicians and laboratory directors are experiencing the downstream effects of these policy changes through altered lead times for reagents, increased capital expenditure considerations for imaging hardware, and the need to justify equipment replacement cycles against a backdrop of elevated acquisition costs. In some cases, health systems are prioritizing investments in high-throughput, cost-efficient platforms that amortize tariff impacts over larger testing volumes. Others are re-evaluating capital allocation between imaging upgrades and molecular diagnostic expansion, seeking the optimal mix to sustain patient access without compromising diagnostic fidelity.

Importantly, the cumulative impact of tariff dynamics also influences strategic partnerships and licensing models. Firms with diversified manufacturing footprints and regional distribution hubs are better positioned to maintain continuity, while smaller vendors are compelled to adopt adaptive pricing strategies or localized support models. Decision-makers must therefore incorporate trade policy sensitivity analyses into procurement and product roadmaps to preserve operational resilience and maintain continuity of diagnostic services.

Granular segmentation insights reveal how disease stage, care setting, test architecture, and imaging modality collectively determine diagnostic adoption patterns and investment priorities

Segmentation-driven insight reveals distinct demand and operational patterns across disease stage, end-user profiles, test types, and technology modalities. When considering disease stage, advanced-stage workflows emphasize confirmatory testing and molecular profiling to inform targeted therapies, whereas early-stage pathways prioritize high-sensitivity screening approaches and minimally invasive diagnostics that support curative interventions. This dichotomy drives differential adoption curves for invasive versus noninvasive modalities.

Across end users, ambulatory care settings and diagnostic centers prioritize rapid turnaround, ease of sample collection, and cost-effective assays to support high-volume screening and triage; hospitals emphasize comprehensive diagnostic capabilities including image-guided biopsies and integrated molecular pathology; research laboratories focus on assay development and validation, often leveraging next-generation sequencing and investigational biomarkers to advance translational pipelines. These end-user imperatives shape procurement decisions and influence which product attributes-such as automation, throughput, and regulatory status-are prioritized in purchasing evaluations.

Test-type differentiation further clarifies market dynamics. Biomarker testing subdivides into genetic markers and protein markers, with genetic markers comprising circulating tumor DNA tests and microRNA assays, and protein markers encompassing AFP tests and DCP assays. Biopsy modalities include core needle biopsy and fine needle aspiration, each with trade-offs in tissue yield and complication risk. Genetic testing techniques span next-generation sequencing and PCR analysis, offering distinct profiles in breadth of coverage and turnaround. Imaging technologies include CT, MRI, PET, and ultrasound, with each modality delivering unique strengths in lesion detection, staging, and treatment planning. Taken together, these layered segmentation dimensions inform where investment in clinical validation, workflow integration, and payor engagement will yield the highest clinical and commercial impact.

Finally, technology-based segmentation mirrors testing categories but highlights modality-specific adoption drivers: ultrasound offers portability and cost-efficiency for screening, CT and MRI provide cross-sectional detail for staging, and PET contributes metabolic characterization that refines staging and therapeutic response assessment. Strategic initiatives that align product design and evidence generation with these segmented needs increase the likelihood of clinical adoption and sustained utilization across care settings.

Comparative regional dynamics demonstrate how healthcare infrastructure, reimbursement pathways, and capacity investments are shaping diagnostic adoption across major global markets

Regional dynamics exhibit meaningful heterogeneity driven by healthcare infrastructure, regulatory frameworks, reimbursement mechanisms, and clinical practice patterns. In the Americas, diagnostic ecosystems emphasize rapid innovation adoption within networked health systems and academic centers, fueling demand for integrated molecular and imaging solutions in tertiary hospitals and ambulatory diagnostic networks. This region often leads in the translation of clinical trial evidence into practice and demonstrates a strong appetite for advanced molecular profiling to support precision oncology initiatives.

Europe, Middle East & Africa presents a mosaic of adoption environments. Certain European markets demonstrate structured reimbursement pathways and centralized reference laboratories that facilitate standardized implementation of validated assays, while other geographies within the region contend with variability in access and resource constraints. Middle Eastern and African health systems are increasingly investing in diagnostic capacity building, with targeted initiatives to expand imaging infrastructure and laboratory capabilities that can accommodate both conventional biomarkers and emerging molecular assays.

Asia-Pacific is characterized by rapid infrastructure investment, diverse payer models, and strong domestic manufacturing capacities in select markets. High-capacity referral centers in major metropolitan areas drive demand for both high-resolution imaging and advanced genomic testing, while regional programs focused on early detection are accelerating uptake of noninvasive biomarkers. Across all regions, cross-border collaboration in clinical validation and multi-center studies is becoming a practical mechanism to generate the evidence needed for broader adoption and regulatory alignment.

Competitive and partnership dynamics reveal that integrated portfolios, robust evidence strategies, and supply chain resilience determine long-term positioning in diagnostic markets

Competitive dynamics in liver cancer diagnostics are defined by a mix of established diagnostic manufacturers, specialized molecular diagnostics firms, imaging vendors, and clinical laboratory networks. Market leaders sustain differentiated positions through broad portfolios that span imaging hardware, assay kits, and integrated software solutions that facilitate data interpretation and workflow integration. Mid-sized firms and innovative start-ups contribute by advancing niche assays, next-generation sequencing applications, and minimally invasive biomarker panels that address unmet needs in early detection and molecular subtyping.

Strategic partnerships between diagnostic developers and academic centers accelerate clinical validation and support the generation of real-world evidence necessary for guideline inclusion. Companies that invest in comprehensive clinician education, health economic dossiers, and payer engagement accrue advantages in adoption speed. Additionally, vendors that provide end-to-end solutions-encompassing sample logistics, centralized testing services, and interpretive reporting-are increasingly attractive to hospital systems and diagnostic centers seeking to minimize internal operational burden.

Supply chain resilience, regulatory preparedness, and scalability of manufacturing remain critical differentiators. Organizations that demonstrate the ability to scale reagent production, secure multi-regional regulatory clearances, and maintain service networks in clinical settings are better positioned to capture clinical partnerships and long-term contracts with health systems. For product teams and commercial leaders, the imperative is to align evidence-generation strategies with clinical workflow integration and payer pathways to translate technological advantage into durable clinical adoption.

Actionable strategic priorities for product, clinical, and commercial teams to accelerate adoption, mitigate supply risks, and demonstrate sustained clinical value

Industry leaders should prioritize a cohesive strategy that aligns product development, clinical evidence generation, and go-to-market models to maximize clinical uptake and commercial traction. Investing in prospective studies that demonstrate clinical utility in early-stage detection and treatment stratification will materially influence guideline adoption and payer support. Concurrently, companies should develop implementation roadmaps tailored to ambulatory care, diagnostic centers, hospitals, and research laboratories to ensure solutions are optimized for the operational realities of each setting.

Operationally, building flexible manufacturing footprints and regional distribution channels reduces exposure to trade-related cost fluctuations and ensures continuity of supply. Strategic collaborations with academic medical centers and large hospital networks accelerate clinical validation and create reference sites that catalyze peer adoption. On the commercial front, aligning pricing models with demonstrated health economic benefits and offering tiered service options-ranging from centralized testing to near-patient platforms-can expand addressable use cases across diverse care settings.

Finally, leaders should invest in clinician-facing education and decision-support tools that integrate molecular, protein, and imaging data into actionable reports. These tools shorten the adoption curve by reducing interpretation friction and demonstrating clear pathways from diagnostic output to therapeutic decision. Taken together, these actions will enable organizations to scale responsibly while delivering clinically meaningful improvements in patient pathways.

A mixed-methods research approach combining expert interviews, clinical literature synthesis, and technology assessments to validate operational and clinical insights

This analysis synthesizes primary and secondary evidence sources using a mixed-methods approach that balances quantitative validation with qualitative contextualization. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities and strategic intent. These perspectives were systematically coded to identify recurring themes in diagnostic adoption, workflow integration, and payer engagement.

Secondary research involved a structured review of peer-reviewed clinical literature, regulatory guidance documents, and professional society recommendations to ground insights in current standards of care and evidence thresholds. Technology assessments evaluated analytic performance characteristics, platform interoperability, and workflow considerations for molecular assays, biopsy techniques, and imaging modalities. Supply chain and policy analyses incorporated publicly available trade and procurement information to assess potential impacts on sourcing and capital investment decisions.

Where possible, findings were triangulated across multiple data streams to enhance validity. Limitations are acknowledged, including variability in regional data availability and the evolving nature of clinical validation for emerging biomarkers. To mitigate these constraints, sensitivity analyses and expert validation workshops were employed, ensuring the recommendations reflect both empirical evidence and practical feasibility for implementation across varied care settings.

Concluding synthesis emphasizing how coordinated investment in evidence generation, workflow integration, and supply resilience will shape diagnostic leadership

In summary, the diagnostic landscape for liver cancer is transitioning toward integrated, multi-modal approaches that balance sensitivity, specificity, and operational feasibility across care settings. Technological advances in genomic assays and imaging continue to expand the diagnostic toolkit, enabling earlier detection and more precise staging that inform therapeutic decision-making. Policy and procurement dynamics, including tariff-related effects, are prompting more strategic sourcing and capital planning to preserve access and operational continuity.

Segmentation analyses indicate that tailored strategies addressing the distinct needs of early versus advanced disease stages, and the specific operational constraints of ambulatory centers, hospitals, diagnostic centers, and research labs, will drive the most sustainable adoption. Regional differences underscore the importance of localized evidence generation, reimbursement alignment, and capacity-building initiatives. Competitive trajectories favor organizations that integrate robust clinical validation, scalable manufacturing, and pragmatic commercial models that lower barriers to adoption.

Collectively, these themes point to an inflection point where coordinated investment in evidence, workflow integration, and supply chain resilience will determine which technologies and providers deliver measurable clinical benefit at scale. Stakeholders that act decisively to align clinical evidence, commercial strategy, and operational readiness will be best positioned to improve diagnostic pathways and patient outcomes in liver cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Diagnostics Market, by Disease Stage

  • 8.1. Advanced Stage
  • 8.2. Early Stage

9. Liver Cancer Diagnostics Market, by Test Type

  • 9.1. Biomarkers
    • 9.1.1. Genetic Markers
      • 9.1.1.1. ctDNA Tests
      • 9.1.1.2. MicroRNA Tests
    • 9.1.2. Protein Markers
      • 9.1.2.1. AFP Tests
      • 9.1.2.2. DCP Tests
  • 9.2. Biopsy
    • 9.2.1. Core Needle Biopsy
    • 9.2.2. Fine Needle Aspiration
  • 9.3. Genetic Testing
    • 9.3.1. Next-Generation Sequencing
    • 9.3.2. PCR Analysis

10. Liver Cancer Diagnostics Market, by Technology

  • 10.1. CT Scan
  • 10.2. MRI
  • 10.3. PET
  • 10.4. Ultrasound

11. Liver Cancer Diagnostics Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
  • 11.4. Research Laboratories

12. Liver Cancer Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Cancer Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Cancer Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Liver Cancer Diagnostics Market

16. China Liver Cancer Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Amgen inc
  • 17.7. Argon Medical Devices, Inc.
  • 17.8. Bayer AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. bioMerieux SA
  • 17.12. Boston Scientific Corporation
  • 17.13. Danaher Corporation
  • 17.14. Epigenomics AG
  • 17.15. F. Hoffmann-La Roche Ltd.
  • 17.16. Hologic, Inc.
  • 17.17. Illumina, Inc.
  • 17.18. QIAGEN N.V.
  • 17.19. Siemens Healthineers AG
  • 17.20. Sysmex Corporation
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CTDNA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MICRORNA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AFP TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DCP TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PCR ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 180. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 210. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 220. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)